This morning, Supreme Pharamaceuticals announced it had received several updates from Health Canada regarding its cultivation licence pursuant to the access to cannabis for medical purposes regulations. Management said Health Canada was in the process of testing its dried cannabis samples and has removed the previous production and storage capacity of the licence, allowing Supreme to store up to $150-million worth of cannabis at any given time.
“We are pleased to be making progress with Health Canada,” said CEO John Fowler. “The forthcoming approval to sell cannabis genetics is one leg of our B2B sales model, allowing us to monetize our genetic inventory. As we await an update on the sales approval, we continue to cultivate and build our inventory in advance of sales approval.”
Bottomley says a sales license for Supreme could be just around the corner, and thinks there are a number of recent positives.
“Although a lack of sales license continues to represent a significant overhang, we consider this update an incremental positive indicator, along with Health Canada’s recent announcement that it will be adding more resources to streamline the ACMPR application process,” the analyst says. “We believe Supreme’s current valuation is attractive ahead of this potential major near-term catalyst, and we would remain buyers at current trading levels.”
In a research update to clients today, Bottomley maintained his “Speculative Buy” rating and one-year price target of $2.10 on Supreme Pharmaceuticals, implying a return of 60.3 per cent at the time of publication.
Bottomley thinks Supreme will post EBITDA of negative $5.4-million on revenue of zero in 2017. He expects those numbers will improve to EBITDA of positive $3.8-million on a topline of $22-million the following year.
Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]
He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]
Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]
With the integration of Shaw Communications underway, RBC analyst Drew McReynolds says Rogers Communications (Rogers Communications Stock Quote, Chart, News,… [Read More]
Following fourth quarter results he describes as "stronger than expected", Beacon Securities analyst Russell Stanley has raised his price target… [Read More]
Ahead if its first quarter results, Citi analyst Filippo Falorni says there is not much to like about Molson Coors… [Read More]